AFFILIATIONS
1 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
2 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
3 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
4 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
5 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
6 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
ABSTRACT
Introduction
Cousins represent a potential alternative donor source for haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Ethical barriers preclude randomized controlled trials (RCTs) designed to directly compare outcomes between sibling-donor and cousin-donor haplo-HSCT, and prognostic differences between these two donor types remain controversial. In this study, we applied target trial emulation (TTE) to retrospective clinical cohort data to generate causal estimates analogous to those from RCTs, and systematically compared clinical outcomes of haplo-HSCT using sibling versus cousin donors in patients with hematological malignancies.
Methods
Adult patients with hematological malignancies who underwent haplo-HSCT at The First Affiliated Hospital of Soochow University between 2017 and 2024 were enrolled and stratified by donor type (cousin-donor group vs. sibling-donor group). Primary endpoints included overall survival (OS), disease-free survival (DFS), and graft-versus-host-disease- and relapse-free survival (GRFS). Secondary endpoints comprised the cumulative incidences of relapse, acute GVHD (aGVHD), and chronic GVHD (cGVHD).
The TTE analytical framework was established in accordance with the TARGET reporting guidelines. Intention-to-treat analysis was adopted as the primary analytical approach. Overlap weighting and inverse probability weighting (IPW) were implemented to balance baseline covariates across groups. E-values were calculated to assess potential unmeasured confounding, and recoding of donor classification was performed for sensitivity analyses.
Results
A total of 662 adult patients undergoing haplo-HSCT were included, consisting of 530 patients with acute leukemia, 86 with myelodysplastic syndrome/myeloproliferative neoplasms, 24 with chronic myeloid leukemia, and 22 with non-Hodgkin lymphoma. There were 126 patients in the cousin donor group and 536 in the sibling donor group. After inverse probability weighting, the absolute standardized mean differences of all baseline characteristics between groups were less than 0.1; the mean truncated overlap weight was 0.128, indicating adequate covariate balance.
During follow-up, donor type (cousin vs. sibling donor) exerted no significant impact on OS (HR=1.18, 95%CI: 0.66–2.11), DFS (HR=1.03, 95%CI: 0.60–1.75), or GRFS (HR=1.15, 95%CI: 0.75–1.77). In addition, cousin donors were not associated with a higher risk of post-transplant relapse compared with sibling donors (HR=1.04, p=0.927). Regarding GVHD-related outcomes, cousin donor transplantation showed a trend toward an increased risk of aGVHD (HR=1.34, 95%CI: 0.83–2.16) and a trend toward a reduced risk of cGVHD (HR=0.71, 95%CI: 0.37–1.36), though neither difference reached statistical significance. Sensitivity analyses validated the robustness of the TTE findings.
Conclusion
Findings from this TTE study suggest that cousins can serve as a feasible alternative donor source when suitable sibling donors are unavailable in clinical practice.
DISCLOSURES
Xinyuan Gu: No relevant conflicts of interest to declare.